Table 2 Mean coinhibition by drug mechanism

Microtubule depolymerizers

benomyl; nocodazole

5

0.73

Dfr1 inhibitors

methotrexate

8

0.62

Ribonucleotide reductase inhibitors

hydroxyurea

3

0.62

Ionophores

nigericin

4

0.61

Metabolites

sphingosine

4

0.61

Fas1 inhibitors

cerulenin; 1-3 diallylurea

3

0.51

Dopamine antagonists

chlorpromazine; trifluoperazine

4

0.48

mTOR inhibitors

rapamycin; caffeine

14

0.45

Calcium channel blockers

amiodarone

3

0.47

Acc1 inhibitors

tofa

3

0.47

Antineoplastic antibiotics

bleomycin

3

0.45

Iron chelators

curcumin

10

0.45

Statins

atorvastatin; cerivastatin; fluvastatin; itavastatin

6

0.44

Aclacinomycin antibiotics

aclarubicin

2

0.42

Cell wall inhibitors

caspofungin; ergokonin

6

0.42

Lcb1/Lcb2 inhibitors

myriocin

2

0.41

FK506; calcineurin inhibitors

ascomycin; tacrolimus

2

0.40

DNA topoisomerase I inhibitors

camptothecin

3

0.38

N-linked glycosylation inhibitors

tunicamycin

4

0.38

Translation inhibitors

anisomycin; cycloheximide

4

0.37

Azoles

clotrimazole; cyproconazole; fluconazole; myclobutanil; voriconazole

6

0.36

Anthracycline antibiotics

daunorubicin; doxorubicin; epirubicin; ravidomycin

11

0.35

Erg1 inhibitors

butenafine; naftitine; terbinafine

6

0.34

Pyrimidine antagonists

5-fluorouracil; flucytosine;

5-fluorouridine; carmofur;

5-fluorocytosine

7

0.31

Erg2 inhibitors

alverine citrate; dyclonine; fenpropimorph; haloperidol

9

0.28

Transcriptional elongation inhibitors

6-azauridine; 6-azauracil; mycophenolic acid

11

0.25

Alkylating agents

mechlorethamine; melphalan; methyl methanesulfonate; mitomycin C

2

0.24